Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics in the Diagnosis and Prognosis of VAP

ConditionVentilator Associated Pneumonia (VAP)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-70

SponsorEsraa Hamdy Thabit Riad

About this trial

mechanically ventilated for 48 hours or more and subsequently develop ventilator-associated pneumonia (VAP). After obtaining approval from the local ethical committee at the Faculty of Medicine, El-Minia University, and informed consent from first-degree relatives, patients will be enrolled and classified into two groups based on clinical outcomes: Group A (survivors with successful extubation) and Group B (non-survivors with prolonged mechanical ventilation and/or 30-day mortality). Prolonged mechanical ventilation (PMV) is defined as ≥21 days of ventilation. Blood samples will be collected from participants to measure heparin-binding protein (HBP), mean platelet volume (MPV), and the MPV-to-platelet count (PC) ratio. Laboratory analysis will be blinded to the clinical outcome group to ensure objectivity. The study aims to investigate the potential of these biomarkers in predicting prognosis and guiding clinical decisions in patients with VAP.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Patients < 18 years old<70years 2. MV for more than 48 h. 3 . Signs of VAP according to clinical and radiological data , Modified Clinical Pulmonary Infection Score (CPIS) will be calculated for the patients and will be included when CPIS > 6 . Modified CPIS will be calculated without considering culture results.(12)

Disqualifiers

None

Trial population

Adult patients (aged 18-70 years) admitted to the intensive care unit (ICU) at El-Minia University Hospitals, who are mechanically ventilated for more than 48 hours and subsequently develop ventilator-associated pneumonia (VAP). All participants must fulfill the clinical and radiological criteria for VAP with a Modified Clinical Pulmonary Infection Score (CPIS) \>6.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

heparin binding protien
Diagnostic test
compare between Heparin binding protien and platelet count and mean platelet volume kinetics in diagnosis and prognosis of VAP

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

HBP levels in survivors and non survivors patients of VAP measured by ng\ ml using ElISAImmunoassay

To determine whether elevated HBP levels , change in platelet count and mean platelet volume kinetics are associated with mortality and prolonged mechanical ventilation in patients with VAP.

Time frame

within 30 days after VAP diagnosis

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Esraa Hamdy Thabit Riad

Lead sponsor

Minia University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: